News headlines about Pluristem Therapeutics (NASDAQ:PSTI) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pluristem Therapeutics earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.5280652316056 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the headlines that may have effected Accern’s scoring:
- Eye-Catching Hot Stocks – Pluristem Therapeutics Inc. (NASDAQ: PSTI) – The Investor Guide (wallstreetnews24.com)
- Marathon Asset Management Llp Trimmed By $8.76 Million Its C H … – Hill Country Times (hillcountrytimes.com)
- Hot Stock’s Trend Recap – Pluristem Therapeutics Inc., (NASDAQ: PSTI) – Stock Watch (stocksnewstimes.com)
- Pluristem Therapeutics Inc. (NASDAQ:PSTI) – Comprehensive Stock Analysis – Nasdaq Journal (press release) (nasdaqjournal.com)
- Pluristem Therapeutics (PSTI) Downgraded by ValuEngine (americanbankingnews.com)
Shares of Pluristem Therapeutics (NASDAQ PSTI) traded down $0.04 on Friday, hitting $1.45. The stock had a trading volume of 116,737 shares, compared to its average volume of 290,954. Pluristem Therapeutics has a 1 year low of $1.04 and a 1 year high of $2.12. The stock has a market capitalization of $152.55, a P/E ratio of -4.53 and a beta of 0.09.
PSTI has been the topic of a number of recent research reports. Seaport Global Securities restated a “buy” rating and issued a $5.00 target price on shares of Pluristem Therapeutics in a research note on Friday, October 6th. Maxim Group restated a “buy” rating and issued a $2.00 target price on shares of Pluristem Therapeutics in a research note on Tuesday, September 5th. ValuEngine downgraded Pluristem Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday. HC Wainwright restated a “buy” rating and issued a $3.50 target price on shares of Pluristem Therapeutics in a research note on Thursday, November 9th. Finally, Zacks Investment Research upgraded Pluristem Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. Pluristem Therapeutics currently has a consensus rating of “Buy” and an average price target of $3.83.
TRADEMARK VIOLATION NOTICE: “Pluristem Therapeutics (PSTI) Earning Somewhat Positive News Coverage, Accern Reports” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.com-unik.info/2017/12/24/pluristem-therapeutics-psti-earning-somewhat-positive-news-coverage-accern-reports.html.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.